Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Le Merdy M, Fan J, Bolger MB, Lukacova V, Spires J, Tsakalozou E, Patel V, Xu L, Stewart S, Chockalingam A, Narayanasamy S, Rouse R, Matta M, Babiskin A, Kozak D, Choi S, Zhang L, Lionberger R, Zhao L.

AAPS J. 2019 May 20;21(4):65. doi: 10.1208/s12248-019-0334-x.

PMID:
31111305
2.

Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism.

Ladumor MK, Bhatt DK, Gaedigk A, Sharma S, Thakur A, Pearce RE, Leeder JS, Bolger MB, Singh S, Prasad B.

Drug Metab Dispos. 2019 Aug;47(8):818-831. doi: 10.1124/dmd.119.086462. Epub 2019 May 17.

PMID:
31101678
3.

Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus.

Hens B, Bolger MB.

J Pharm Sci. 2019 Jan;108(1):305-315. doi: 10.1016/j.xphs.2018.10.041. Epub 2018 Nov 2.

PMID:
30395828
4.

The Irrelevance of In Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping.

Bolger MB, Macwan JS, Sarfraz M, Almukainzi M, Löbenberg R.

J Pharm Sci. 2019 Jan;108(1):268-278. doi: 10.1016/j.xphs.2018.09.036. Epub 2018 Oct 11.

PMID:
30316900
5.

Pathway-based predictive approaches for non-animal assessment of acute inhalation toxicity.

Clippinger AJ, Allen D, Behrsing H, BéruBé KA, Bolger MB, Casey W, DeLorme M, Gaça M, Gehen SC, Glover K, Hayden P, Hinderliter P, Hotchkiss JA, Iskandar A, Keyser B, Luettich K, Ma-Hock L, Maione AG, Makena P, Melbourne J, Milchak L, Ng SP, Paini A, Page K, Patlewicz G, Prieto P, Raabe H, Reinke EN, Roper C, Rose J, Sharma M, Spoo W, Thorne PS, Wilson DM, Jarabek AM.

Toxicol In Vitro. 2018 Oct;52:131-145. doi: 10.1016/j.tiv.2018.06.009. Epub 2018 Jun 20. Review.

6.

Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series.

Daga PR, Bolger MB, Haworth IS, Clark RD, Martin EJ.

Mol Pharm. 2018 Mar 5;15(3):821-830. doi: 10.1021/acs.molpharmaceut.7b00972. Epub 2018 Feb 1.

PMID:
29337578
7.

Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 2. Rational Bioavailability Design by Global Sensitivity Analysis To Identify Properties Affecting Bioavailability.

Daga PR, Bolger MB, Haworth IS, Clark RD, Martin EJ.

Mol Pharm. 2018 Mar 5;15(3):831-839. doi: 10.1021/acs.molpharmaceut.7b00973. Epub 2018 Feb 1.

PMID:
29337562
8.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:610-625. doi: 10.1016/j.ejps.2016.10.036. Epub 2016 Nov 2.

PMID:
27816631
9.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:626-642. doi: 10.1016/j.ejps.2016.09.037. Epub 2016 Sep 28.

PMID:
27693299
10.

IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.

Margolskee A, Darwich AS, Pepin X, Pathak SM, Bolger MB, Aarons L, Rostami-Hodjegan A, Angstenberger J, Graf F, Laplanche L, Müller T, Carlert S, Daga P, Murphy D, Tannergren C, Yasin M, Greschat-Schade S, Mück W, Muenster U, van der Mey D, Frank KJ, Lloyd R, Adriaenssen L, Bevernage J, De Zwart L, Swerts D, Tistaert C, Van Den Bergh A, Van Peer A, Beato S, Nguyen-Trung AT, Bennett J, McAllister M, Wong M, Zane P, Ollier C, Vicat P, Kolhmann M, Marker A, Brun P, Mazuir F, Beilles S, Venczel M, Boulenc X, Loos P, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:598-609. doi: 10.1016/j.ejps.2016.09.027. Epub 2016 Sep 23.

PMID:
27671970
11.
12.

In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.

Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, Brouwers J, Flanagan T, Harwood M, Heinen C, Holm R, Juretschke HP, Kubbinga M, Lindahl A, Lukacova V, Münster U, Neuhoff S, Nguyen MA, Peer Av, Reppas C, Hodjegan AR, Tannergren C, Weitschies W, Wilson C, Zane P, Lennernäs H, Langguth P.

Eur J Pharm Sci. 2014 Jun 16;57:99-151. doi: 10.1016/j.ejps.2014.02.010. Epub 2014 Mar 15. Review.

PMID:
24637348
13.

PBPK models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjögren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J.

Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21. Review.

PMID:
24060672
14.

Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.

Wang Y, Wang Z, Zuo Z, Tomlinson B, Lee BT, Bolger MB, Chow MS.

AAPS J. 2013 Jul;15(3):787-96. doi: 10.1208/s12248-013-9479-1. Epub 2013 Apr 19.

15.

Modeling of absorption.

Woltosz WS, Bolger MB, Lukacova V.

Methods Mol Biol. 2012;929:313-36.

PMID:
23007435
16.

Provisional biopharmaceutical classification of some common herbs used in Western medicine.

Waldmann S, Almukainzi M, Bou-Chacra NA, Amidon GL, Lee BJ, Feng J, Kanfer I, Zuo JZ, Wei H, Bolger MB, Löbenberg R.

Mol Pharm. 2012 Apr 2;9(4):815-22. doi: 10.1021/mp200162b. Epub 2012 Mar 14.

PMID:
22352942
17.

Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.

De Zordi N, Moneghini M, Kikic I, Grassi M, Del Rio Castillo AE, Solinas D, Bolger MB.

Eur J Pharm Biopharm. 2012 May;81(1):131-41. doi: 10.1016/j.ejpb.2012.01.002. Epub 2012 Jan 17.

PMID:
22266263
18.

In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.

Abuasal BS, Bolger MB, Walker DK, Kaddoumi A.

Mol Pharm. 2012 Mar 5;9(3):492-504. doi: 10.1021/mp200275j. Epub 2012 Feb 2.

PMID:
22264132
19.

Predicting the effect of fed-state intestinal contents on drug dissolution.

Gamsiz ED, Ashtikar M, Crison J, Woltosz W, Bolger MB, Carrier RL.

Pharm Res. 2010 Dec;27(12):2646-56. doi: 10.1007/s11095-010-0264-x. Epub 2010 Oct 21.

PMID:
20963629
20.

Mutagenesis and cysteine scanning of transmembrane domain 10 of the human dipeptide transporter.

Xu L, Haworth IS, Kulkarni AA, Bolger MB, Davies DL.

Pharm Res. 2009 Oct;26(10):2358-66. doi: 10.1007/s11095-009-9952-9. Epub 2009 Aug 14.

21.

Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Bolger MB, Lukacova V, Woltosz WS.

AAPS J. 2009 Jun;11(2):353-63. doi: 10.1208/s12248-009-9111-6. Epub 2009 May 12.

22.

Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.

Lukacova V, Woltosz WS, Bolger MB.

AAPS J. 2009 Jun;11(2):323-34. doi: 10.1208/s12248-009-9107-2. Epub 2009 May 9.

23.

Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects.

Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB.

AAPS J. 2009 Mar;11(1):45-53. doi: 10.1208/s12248-008-9079-7. Epub 2009 Jan 29. Review.

24.

Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.

Tubic-Grozdanis M, Bolger MB, Langguth P.

AAPS J. 2008;10(1):213-26. doi: 10.1208/s12248-008-9023-x. Epub 2008 Apr 2.

25.

Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.

Deng J, Sanchez T, Al-Mawsawi LQ, Dayam R, Yunes RA, Garofalo A, Bolger MB, Neamati N.

Bioorg Med Chem. 2007 Jul 15;15(14):4985-5002. Epub 2007 Apr 25.

PMID:
17502148
26.

In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.

Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P.

Pharm Res. 2006 Aug;23(8):1712-20.

PMID:
16832615
27.
29.

Pressure-sensitive and -insensitive coupling in gamma-aminobutyric acid(A) receptors.

Davies DL, McCauley LD, Bolger MB, Alkana RL.

Psychopharmacology (Berl). 2001 Oct;157(4):401-10.

PMID:
11605100
30.

Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

Agoram B, Woltosz WS, Bolger MB.

Adv Drug Deliv Rev. 2001 Oct 1;50 Suppl 1:S41-67. Review.

PMID:
11576695
31.

Biopharmaceutics of transmucosal peptide and protein drug administration: role of transport mechanisms with a focus on the involvement of PepT1.

Lee VH, Chu C, Mahlin ED, Basu SK, Ann DK, Bolger MB, Haworth IS, Yeung AK, Wu SK, Hamm-Alvarez S, Okamoto CT.

J Control Release. 1999 Nov 1;62(1-2):129-40. Review.

PMID:
10518644
32.

In vivo and in vitro hyperbaric studies in mice suggest novel sites of action for ethanol.

Davies DL, Bolger MB, Brinton RD, Finn DA, Alkana RL.

Psychopharmacology (Berl). 1999 Feb;141(4):339-50.

PMID:
10090641
33.

Structure, function, and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1.

Bolger MB, Haworth IS, Yeung AK, Ann D, von Grafenstein H, Hamm-Alvarez S, Okamoto CT, Kim KJ, Basu SK, Wu S, Lee VH.

J Pharm Sci. 1998 Nov;87(11):1286-91.

PMID:
9811478
34.

Proton-driven dipeptide uptake in primary cultured rabbit conjunctival epithelial cells.

Basu SK, Haworth IS, Bolger MB, Lee VH.

Invest Ophthalmol Vis Sci. 1998 Nov;39(12):2365-73.

PMID:
9804145
35.

Molecular identification of a role for tyrosine 167 in the function of the human intestinal proton- coupled dipeptide transporter (hPepT1).

Yeung AK, Basu SK, Wu SK, Chu C, Okamoto CT, Hamm-Alvarez SF, von Grafenstein H, Shen WC, Kim KJ, Bolger MB, Haworth IS, Ann DK, Lee VH.

Biochem Biophys Res Commun. 1998 Sep 8;250(1):103-7.

PMID:
9735340
36.

Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.

Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, Gee KW.

J Pharmacol Exp Ther. 1997 Mar;280(3):1284-95.

PMID:
9067315
37.

Synthesis and in vitro activity of 3 beta-substituted-3 alpha-hydroxypregnan-20-ones: allosteric modulators of the GABAA receptor.

Hogenkamp DJ, Tahir SH, Hawkinson JE, Upasani RB, Alauddin M, Kimbrough CL, Acosta-Burruel M, Whittemore ER, Woodward RM, Lan NC, Gee KW, Bolger MB.

J Med Chem. 1997 Jan 3;40(1):61-72.

PMID:
9016329
38.

In vitro and in vivo activity of 16,17-dehydro-epipregnanolones: 17,20-bond torsional energy analysis and D-ring conformation.

Bolger MB, Wieland S, Hawkinson JE, Xia H, Upasani R, Lan NC.

Pharm Res. 1996 Oct;13(10):1488-94.

PMID:
8899839
39.

Low level hyperbaric antagonism of diazepam's locomotor depressant and anticonvulsant properties in mice.

Davies DL, Bejanian M, Parker ES, Mørland J, Bolger MB, Brinton RD, Alkana RL.

J Pharmacol Exp Ther. 1996 Feb;276(2):667-75.

PMID:
8632335
40.

The neuroactive steroid 3 alpha-hydroxy-5 beta-pregnan-20-one is a two-component modulator of ligand binding to the GABAA receptor.

Hawkinson JE, Kimbrough CL, McCauley LD, Bolger MB, Lan NC, Gee KW.

Eur J Pharmacol. 1994 Oct 14;269(2):157-63.

PMID:
7851492
42.

Pharmacology of a GABAA receptor coupled steroid recognition site.

Gee KW, Lan NC, Bolger MB, Wieland S, Belelli D, Chen JS.

Adv Biochem Psychopharmacol. 1992;47:111-7. Review. No abstract available.

PMID:
1354914
43.

Differential responses of expressed recombinant human gamma-aminobutyric acidA receptors to neurosteroids.

Lan NC, Gee KW, Bolger MB, Chen JS.

J Neurochem. 1991 Nov;57(5):1818-21.

PMID:
1655982
44.

Identification and characterization of a pregnane steroid recognition site that is functionally coupled to an expressed GABAA receptor.

Lan NC, Bolger MB, Gee KW.

Neurochem Res. 1991 Mar;16(3):347-56. Review. No abstract available.

PMID:
1664061
45.

Computer modeling of combining site structure of anti-hapten monoclonal antibodies.

Bolger MB, Sherman MA.

Methods Enzymol. 1991;203:21-45. Review. No abstract available.

PMID:
1762557
46.

Interaction of yeast transcription factor IIIC with dimeric Schizosaccharomyces pombe tRNA(Ser)-tRNA(Met) genes.

Johnson DL, Nichols M, Bolger MB, Wilson S.

J Biol Chem. 1989 Nov 15;264(32):19221-7.

47.

Anticonvulsant profile of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one.

Belelli D, Bolger MB, Gee KW.

Eur J Pharmacol. 1989 Jul 18;166(2):325-9.

PMID:
2792198
48.

Thyroid hormone analog inhibition of hepatic 5'-iodothyronine deiodinase activity.

Shulkin BL, Bolger MB, Utiger RD.

J Endocrinol Invest. 1988 Oct;11(9):657-61.

PMID:
3221042
49.

Analysis of idiotypic and anti-idiotypic antibodies as models of receptor and ligand.

Linthicum DS, Bolger MB, Kussie PH, Albright GM, Linton TA, Combs S, Marchetti D.

Clin Chem. 1988 Sep;34(9):1676-80. Review.

50.

Steroid modulation of the chloride ionophore in rat brain: structure-activity requirements, regional dependence and mechanism of action.

Gee KW, Bolger MB, Brinton RE, Coirini H, McEwen BS.

J Pharmacol Exp Ther. 1988 Aug;246(2):803-12.

PMID:
2841455

Supplemental Content

Loading ...
Support Center